Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > March 6, 2025
Daily News
March 6, 2025
- Novo Bolsters Wegovy Label in Japan with CV Outcome Data
March 6, 2025
- New LDP Project Team Holds Hearing for Govt’s Startup Measures
March 6, 2025
- Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey
March 6, 2025
- AZ Wins Certification to Allow Use of Pseudonymized Medical Info
March 6, 2025
- CAR-T Therapies Subject to Label Revision over Lymphoid Neoplasm Risk
March 6, 2025
- Safety-Related Label Revision Ordered for Trulicity, CP Inhibitors, and More
March 6, 2025
- DMD Cell Therapy Accepted for FDA Review: Capricor/Nippon Shinyaku
March 6, 2025
- NCCH Launches Pilot for Online Screening of Clinical Trial Participants
March 6, 2025
- MHLW Taking Applications for Subsidies to Support Generic Consolidation, Biosimilars
March 6, 2025
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…